我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • 哥白尼索引
  • 谷歌学术
  • 打开 J 门
  • Genamics 期刊搜索
  • 宇宙IF
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • 普布隆斯
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
  • ICMJE
分享此页面

抽象的

Response of Refractory New Daily Persistent Headache to Intravenous Lidocaine Treatment in a Pediatric Patient

Asra Akbar

New daily persistent headache (NDPH) is defined as a persistent and daily headache from onset. It is a unique headache that typically seen in people without a prior history of headaches. New daily persistent headache (NDPH) is an often medication-refractory headache disorder, currently classified as a primary headache disorder. Several medications including Onabotulinum toxin injections and sphenopalatine ganglion block are currently under investigation and may provide a potential new effective treatment regimen. IV lidocaine has been used for the management of chronic daily headaches, trigeminal autonomic cephalalgias, neuropathic pain, oro-facial, and postoperative pain. We administered IV lidocaine with successful treatment of headache in a refractory NDPH pediatric patient.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证。